Document Type


Publication Date



JGM, Humans, Vitamin D, Proteomics, Vitamins, Neoplasms, Vitamin D Deficiency, Antineoplastic Agents, Receptors, Calcitriol

JAX Source

J Steroid Biochem Mol Biol. 2023;231:106308.







T.S.L. was supported by Grant # IRG-17-183-16 from the American Cancer Society, and from the Sylvester Comprehensive Cancer Center at the Miller School of Medicine, University of Miami. EC was supported by JAX Computational Sciences and JAX Cancer Center (JAXCC) (NCI CCSG - P30CA034196) and by grant NSF 19-500, DMS 1918925/ 1922843.


In this review, we summarize the most recent advances in vitamin D cancer research to provide molecular clarity, as well as its translational trajectory across the cancer landscape. Vitamin D is well known for its role in regulating mineral homeostasis; however, vitamin D deficiency has also been linked to the development and progression of a number of cancer types. Recent epigenomic, transcriptomic, and proteomic studies have revealed novel vitamin D-mediated biological mechanisms that regulate cancer cell self-renewal, differentiation, proliferation, transformation, and death. Tumor microenvironmental studies have also revealed dynamic relationships between the immune system and vitamin D's anti-neoplastic properties. These findings help to explain the large number of population-based studies that show clinicopathological correlations between circulating vitamin D levels and risk of cancer development and death. The majority of evidence suggests that low circulating vitamin D levels are associated with an increased risk of cancers, whereas supplementation alone or in combination with other chemo/immunotherapeutic drugs may improve clinical outcomes even further. These promising results still necessitate further research and development into novel approaches that target vitamin D signaling and metabolic systems to improve cancer outcomes.


This is an open access article under the CC BY-NC-ND license ( nc-nd/4.0/).